SMS 5368
Alternative Names: [F-18]SMS-5368; SMS-5368Latest Information Update: 10 Sep 2025
At a glance
- Originator Siemens Medical Solutions Molecular Imaging
- Class Antineoplastics; Diagnostic agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 26 Apr 2025 Siemens Molecular Imaging initiates enrolment in a phase I/II trial for Prostate cancer in unknown location prior to April 2026
- 26 Apr 2025 Phase-I/II clinical trials in Prostate cancer (Parenteral)
- 26 Apr 2025 Pharmacodynamics data from a phase I/II trial presented at the 120th Annual Meeting of the American Urological Association (AUA-2025)